Progress in therapy for Duchenne muscular dystrophy

Experimental Physiology

Volumn 96, Issue 11, 2011, Pages 1101-1113

  Fairclough, Rebecca J ^a   Bareja, Akshay ^a   Davies, Kay E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; DYSTROPHIN ASSOCIATED PROTEIN COMPLEX; GENTAMICIN; UTROPHIN;

ARTICLE; CELL THERAPY; CODON; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE MUTATION; GENE REPLACEMENT THERAPY; HUMAN; MYOBLAST; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; UPREGULATION;

EID: 80055064588     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2010.053025     Document Type: Article

References (136)

1. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ & den Dunnen JT (2009). Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30, 293-299.
2. Acharyya S, Butchbach MER, Sahenk Z, Wang HT, Saji M, Carathers M, Ringel MD, Skipworth RJE, Fearon KCH, Hollingsworth MA, Muscarella P, Burghes AHM, Rafael-Fortney JA & Guttridge DC (2005). Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421-432.
3. Adams ME, Kramarcy N, Krall SP, Rossi SG, Rotundo RL, Sealock R & Froehner SC (2000). Absence of α-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin. J Cell Biol 150, 1385-1398.
4. Alter J, Lou F, Rabinowitz A, Yin HF, Rosenfeld J, Wilton SD, Partridge TA & Lu QL (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12, 175-177.
5. Amann KJ, Guo AW & Ervasti JM (1999). Utrophin lacks the rod domain actin binding activity of dystrophin. J Biol Chem 274, 35375-35380.
6. Amann KJ, Renley BA & Ervasti JM (1998). A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. J Biol Chem 273, 28419-28423.
7. Ambrosio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP, Canovas M, Vainzof M, Miglino MA & Zatz M (2008). Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul Disord 18, 892-893.
8. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS & Fallon JR (2011). Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108, 762-767.
9. Angus LM, Chakkalakal JV, Mejat A, Eibl JK, Belanger G, Megeney LA, Chin ER, Schaeffer L, Michel RN & Jasmin BJ (2005). Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1 alpha, drives utrophin gene expression at the neuromuscular junction. American Journal of Physiology-Cell Physiology 289, C908-C917.
10. Bareja A (2011). Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research. D.Phil. Thesis, Department of Physiology, Anatomy and Genetics, Oxford University, Oxford, UK.
11. Baxter P (2006). Treatment of the heart in Duchenne muscular dystrophy. Dev Med Child Neurol 48, 163.
12. Benchaouir R, Meregalli M, Farini A, D'Antona G, Belicchi M, Goyenvalle A, Battistelli M, Bresolin N, Bottinelli R, Garcia L & Torrente Y (2007). Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell 1, 646-657.
13. Bhagavati S & Xu W (2004). Isolation and enrichment of skeletal muscle progenitor cells from mouse bone marrow. Biochem Biophys Res Commun 318, 119-124.
14. Bogdanovich S, Perkins KJ, Krag TO & Khurana TS (2004). Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med 82, 102-115.
15. Burton EA, Tinsley JM, Holzfeind PJ, Rodrigues NR & Davies KE (1999). A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 96, 14025-14030.
16. Bushby K, Lochmuller H, Lynn S & Straub V (2009). Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 374, 1849-1856.
17. Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D, Davies KE, Cornelio F, Pozza O, Karpati G, Gilbert R & Mora M (2003). Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 10, 750-757.
18. Chamberlain JS (1997). Dystrophin levels required for genetic correction of Duchenne muscular dystrophy. Basic and Applied Myology 7, 255-257.
19. Chang WJ, Iannaccone ST, Lau KS, Masters BS, McCabe TJ, McMillan K, Padre RC, Spencer MJ, Tidball JG & Stull JT (1996). Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc Natl Acad Sci USA 93, 9142-9147.
20. Chen YW, Zhao P, Borup R & Hoffman EP (2000). Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151, 1321-1336.
21. Clerk A, Morris GE, Dubowitz V, Davies KE & Sewry CA (1993). Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. Histochem J 25, 554-561.
22. Connolly AM, Keeling RM, Mehta S, Pestronk A & Sanes JR (2001). Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice. Neuromuscul Disord 11, 703-712.
23. Connolly AM, Schierbecker J, Renna R & Florence J (2002). High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 12, 917-925.
24. Corbi N, Libri V, Fanciulli M, Tinsley JM, Davies KE & Passananti C (2000). The artificial zinc finger coding gene 'Jazz' binds the utrophin promoter and activates transcription. Gene Ther 7, 1076-1083.
25. Cox GF & Kunkel LM (1997). Dystrophies and heart disease. Curr Opin Cardiol 12, 329-343.
26. Davies KE & Nowak KJ (2006). Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7, 762-773.
27. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM & Davies KE (1997). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727.
28. Dennis CL, Tinsley JM, Deconinck AE & Davies KE (1996). Molecular and functional analysis of the utrophin promoter. Nucleic Acids Res 24, 1646-1652.
29. Di Certo MG, Corbi N, Strimpakos G, Onori A, Luvisetto S, Severini C, Guglielmotti A, Batassa EM, Pisani C, Floridi A, Benassi B, Fanciulli M, Magrelli A, Mattei E & Passananti C (2010). The artificial gene Jazz, a transcriptional regulator of utrophin, corrects the dystrophic pathology in mdx mice. Hum Mol Genet 19, 752-760.
30. Durko M, Allen C, Nalbantoglu J & Karpati G (2010). CT-GalNAc transferase overexpression in adult mice is associated with extrasynaptic utrophin in skeletal muscle fibres. J Muscle Res Cell Motil 31, 181-193.
31. El Fahime E, Mills P, Lafreniere JF, Torrente Y & Tremblay JP (2002). The urokinase plasminogen activator: an interesting way to improve myoblast migration following their transplantation. Exp Cell Res 280, 169-178.
32. El Fahime E, Torrente Y, Caron NJ, Bresolin MD & Tremblay JP (2000). In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity. Exp Cell Res 258, 279-287.
33. Emery AEH (1993). Duchenne muscular dystrophy. Oxford University Press, Oxford.
34. Emery AEH & Muntoni F (2003). Duchenne Muscular Dystrophy. Oxford University Press, Oxford.
35. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB & Davies KE (1990). Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182.
36. Fakhfakh R, Lamarre Y, Skuk D & Tremblay JP (2011). Losartan enhances the success of myoblast transplantation. Cell Transplant, 20. DOI:.
37. Fan Y, Beilharz MW & Grounds MD (1996). A potential alternative strategy for myoblast transfer therapy: the use of sliced muscle grafts. Cell Transplant 5, 421-429.
38. Finkel RS (2010). Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 25, 1158-1164.
39. Fisher R, Tinsley JM, Phelps SR, Squire SE, Townsend ER, Martin JE & Davies KE (2001). Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscular Disorders 11, 713-721.
40. Gauthier-Rouviere C & Bonet-Kerrache A (2009). RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. Biochem Biophys Res Commun 384, 322-328.
41. Gerard C, Forest MA, Beauregard G, Skuk D & Tremblay JP (2011). Fibrin gel improves the survival of transplanted myoblasts. Cell Transplant (in press).
42. Gilbert R, Nalbantoglu J, Petrof BJ, Ebihara S, Guibinga GH, Tinsley JM, Kamen A, Massie B, Davies KE & Karpati G (1999). Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 10, 1299-1310.
43. Goemans NM, Tulinius M, Buyse G, Wilson R, de Kimpe R, van Deutekom JCT & Campion G (2010). 24 week follow-up data from a phase I/IIa extension study of PRO051/GSK2402968 in subjects with Duchenne muscular dystrophy. Neuromusc Disord 20, 639.
44. Gowers WR (1892). A manual of diseases of the nervous system. J & A Churchill, London.
45. Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L & Danos O (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796-1799.
46. Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD & Davies KE (2010). Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18, 198-205.
47. Goyenvalle A & Davies KE (2011a). Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. Skelet Muscle 1, 8.
48. Goyenvalle A & Davies KE (2011b). Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy. Methods Mol Biol 709, 179-196.
49. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS & Sanes JR (1997). Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729-738.
50. Gramolini AO, Angus LM, Schaeffer L, Burton EA, Tinsley JM, Davies KE, Changeux JP & Jasmin BJ (1999). Induction of utrophin gene expression by heregulin in skeletal muscle cells: role of the N-box motif and GA binding protein. Proc Natl Acad Sci U S A 96, 3223-3227.
51. Guglieri M & Bushby K (2010). Molecular treatments in Duchenne muscular dystrophy. Curr Opin Pharmacol 10, 331-337.
52. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L & Blau HM (1992). Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356, 435-438.
53. Hall JK, Banks GB, Chamberlain JS & Olwin BB (2011). Prevention of muscle aging by myofiber-associated satellite cell transplantation. Sci Transl Med 2, 57ra83.
54. Hillier BJ, Christopherson KS, Prehoda KE, Bredt DS & Lim WA (1999). Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science 284, 812-815.
55. Hong F, Lee J, Song JW, Lee SJ, Ahn H, Cho JJ, Ha J & Kim SS (2002). Cyclosporine blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidylprolyl-cis-trans-isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine-induced cytotoxicity. FASEB J 16, 1633-1635.
56. Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion RD, Paris E, Woods EJ, Murphy MP, Dasanu CA, Patel AN, Marleau AM, Leal A & Riordan NH (2010). Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol 260, 75-82.
57. Ishikawa-Sakurai M, Yoshida M, Imamura M, Davies KE & Ozawa E (2004). ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to β-dystroglycan. Hum Mol Genet 13, 693-702.
58. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL & Kole R (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16, 1624-1629.
59. Jearawiriyapaisarn N, Moulton HM, Sazani P, Kole R & Willis MS (2010). Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 85, 444-453.
60. Jung D, Yang B, Meyer J, Chamberlain JS & Campbell KP (1995). Identification and characterization of the dystrophin anchoring site on β-dystroglycan. J Biol Chem 270, 27305-27310.
61. Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, Nabeshima Y & Takeda S (1999). α1-Syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J Biol Chem 274, 2193-2200.
62. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, Koch PA, Shoubridge E, Spence D, Vanasse M, Watters GV, Abrahamowicz M, Duff C & Worton RG (1993). Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol 34, 8-17.
63. Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C, Takehara S, Higaki K, Nakagawa M, Takahashi K, Yamanaka S & Oshimura M (2010). Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol Ther 18, 386-393.
64. Khurana TS & Davies KE (2003). Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2, 379-390.
65. Khurana TS, Watkins SC, Chafey P, Chelly J, Tomé FM, Fardeau M, Kaplan JC & Kunkel LM (1991). Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1, 185-194.
66. Kleopa KA, Drousiotou A, Mavrikiou E, Ormiston A & Kyriakides T (2006). Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum Mol Genet 15, 1623-1628.
67. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C & Kunkel LM (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.
68. Koenig M, Monaco AP & Kunkel LM (1988). The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-228.
69. Krag TO, Bogdanovich S, Jensen CJ, Fischer MD, Hansen-Schwartz J, Javazon EH, Flake AW, Edvinsson L & Khurana TS (2004). Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci USA 101, 13856-13860.
70. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL & Duan D (2009). Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 119, 624-635.
71. Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, Davies KE, Chamberlain JS & Duan D (2010). Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci 123, 2008-2013.
72. Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD & Chamberlain JS (2005). Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12, 1099-1108.
73. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS & Duan D (2005). Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Molecular Therapy: the Journal of the American Society of Gene Therapy 11, 245-256.
74. Love DR, England SB, Speer A, Marsden RF, Bloomfield JF, Roche AL, Cross GS, Mountford RC, Smith TJF & Davies KE (1991). Sequences of junction fragments in the deletion-prone region of the dystrophin gene. Genomics 10, 57-67.
75. McGeachie JK, Grounds MD, Partridge TA & Morgan JE (1993). Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci 119, 169-179.
76. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM & Mendell JR (2010). Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67, 771-780.
77. Manuvakhova M, Keeling K & Bedwell DM (2000). Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6, 1044-1055.
78. Manzur AY & Muntoni F (2009). Diagnosis and new treatments in muscular dystrophies. Postgrad Med J 85, 622-630.
79. Matsumura K, Abe I, Fukuhara M, Fujii K, Ohya Y, Okamura K & Fujishima M (1994). Modulation of circadian rhythm of blood pressure by cortisol in patients with hypopituitarism. Clin Exp Hypertens 16, 55-66.
80. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, McAndrew PE, Rice R, Nagaraja H, Stephens R, Lantry L, Morris GE & Burghes AHM (1995). Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 333, 832-838.
81. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, Bowles D, Gray S, Li C, Galloway G, Malik V, Coley B, Clark KR, Li J, Xiao X, Samulski J, McPhee SW, Samulski RJ & Walker CM (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363, 1429-1437.
82. Miura P, Chakkalakal JV, Boudreault L, Belanger G, Hebert RL, Renaud JM & Jasmin BJ (2009). Pharmacological activation of PPARβ/δ stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 18, 4640-4649.
83. Mizuno Y, Nonaka I, Hirai S & Ozawa E (1993). Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 119, 43-52.
84. Morgan JE & Partridge TA (1992). Cell transplantation and gene therapy in muscular dystrophy. Bioessays 14, 641-645.
85. Morgan JE, Beauchamp JR, Pagel CN, Peckham M, Ataliotis P, Jat PS, Noble MD, Farmer K & Partridge TA (1994). Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162, 486-498.
86. Morrison J, Lu QL, Pastoret C, Partridge T & Bou-Gharios G (2000). T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest 80, 881-891.
87. Moulton HM & Moulton JD (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798, 2296-2303.
88. Partridge TA (1991). Invited review: myoblast transfer: a possible therapy for inherited myopathies? Muscle Nerve 14, 197-212.
89. Partridge TA, Morgan JE, Coulton GR, Hoffman EP & Kunkel LM (1989). Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337, 176-179.
90. Pellegrini KL & Beilharz MW (2011). The survival of myoblasts after intramuscular transplantation is improved when fewer cells are injected. Transplantation 91, 522-526.
91. Perkins KJ, Burton EA & Davies KE (2001). The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy. Nucleic Acids Res 29, 4843-4850.
92. Peters MF, Sadoulet-Puccio HM, Grady RM, Kramarcy NR, Kunkel LM, Sanes JR, Sealock R & Froehner SC (1998). Differential membrane localization and intermolecular associations of α-dystrobrevin isoforms in skeletal muscle. J Cell Biol 142, 1269-1278.
93. Petrof BJ, Shrager JB, Stedman HH, Kelly AM & Sweeney HL (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90, 3710-3714.
94. Pichavant C, Chapdelaine P, Cerri DG, Dominique JC, Quenneville SP, Skuk D, Kornegay JN, Bizario JC, Xiao X & Tremblay JP (2010). Expression of dog microdystrophin in mouse and dog muscles by gene therapy. Mol Ther 18, 1002-1009.
95. Pons F, Nicholson LV, Robert A, Voit T & Leger JJ (1993). Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. Neuromuscul Disord 3, 507-514.
96. Rolland JF, De Luca A, Burdi R, Andreetta F, Confalonieri P & Conte Camerino D (2006). Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline. Neurobiol Dis 24, 466-474.
97. Rybakova IN & Ervasti JM (2005). Identification of spectrin-like repeats required for high affinity utrophin-actin interaction. J Biol Chem 280, 23018-23023.
98. Rybakova IN, Patel JR & Ervasti JM (2000). The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 150, 1209-1214.
99. Sadoulet-Puccio HM, Rajala M & Kunkel LM (1997). Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci USA 94, 12413-12418.
100. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthelemy I, Perani L, Mantero S, Guttinger M, Pansarasa O, Rinaldi C, De Angelis MGC, Torrente Y, Bordignon C, Bottinelli R & Cossu G (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579.
101. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD & Victor RG (2000). Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci USA 97, 13818-13823.
102. Sharp NJ, Kornegay JN & Lane SB (1989). The muscular dystrophies. Semin Vet Med Surg (Small Anim) 4, 133-140.
103. Shrewsbury SB, Cirak S, Guglieri M, Bushby K & Muntoni F (2010). Current progress and preliminary results with the systemic administration trial of AVI-4658, a novel phosphorodiamidate morpholino oligomer (PMO) skipping dystrophin exon 51 in Duchenne muscular dystrophy (DMD). In Neuromuscular Disorders 20, 639-640.
104. Skuk D, Goulet M, Roy B & Tremblay JP (2002). Efficacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: toward defining strategies applicable to humans. Exp Neurol 175, 112-126.
105. Smythe GM, Davies MJ, Paulin D & Grounds MD (2001). Absence of desmin slightly prolongs myoblast proliferation and delays fusion in vivo in regenerating grafts of skeletal muscle. Cell Tissue Res 304, 287-294.
106. Smythe GM & Grounds MD (2000). Exposure to tissue culture conditions can adversely affect myoblast behavior in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant 9, 379-393.
107. Smythe GM & Grounds MD (2001). Absence of MyoD increases donor myoblast migration into host muscle. Exp Cell Res 267, 267-274.
108. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA & Ervasti JM (2009). Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 6, e1000083.
109. Spencer MJ & Tidball JG (1996). Calpain translocation during muscle fiber necrosis and regeneration in dystrophin-deficient mice. Exp Cell Res 226, 264-272.
110. Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R, Gillis JM & Davies KE (2002). Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 11, 3333-3344.
111. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT & Kelly AM (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
112. Thomas GD, Sander M, Lau KS, Huang PL, Stull JT & Victor RG (1998). Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc Natl Acad Sci USA 95, 15090-15095.
113. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM & Davies K (1998). Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4, 1441-1444.
114. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, Byth BC, Knight AE, Kendrick Jones J, Suthers GK, Love DR, Edwards YH & Davies KE (1992). Primary structure of dystrophin-related protein. Nature 360, 591-593.
115. Tinsley JM, Fairclough RJ, Storer R, Wilkes F, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A, Wilson F, Wren S, De Luca A & Davies KE (2011). Daily treatment with SMT C1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One 6, e19189.
116. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI & Davies KE (1996). Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349-353.
117. Tochio H, Zhang Q, Mandal P, Li M & Zhang M (1999). Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat Struct Biol 6, 417-421.
118. Tome FM, Matsumura K, Chevallay M, Campbell KP & Fardeau M (1994). Expression of dystrophin-associated glycoproteins during human fetal muscle development: a preliminary immunocytochemical study. Neuromuscul Disord 4, 343-348.
119. + stem cells in Duchenne muscle patients. Cell Transplant 16, 563-577.
120. Torrente Y, El Fahime E, Caron NJ, Bresolin N & Tremblay JP (2000). Intramuscular migration of myoblasts transplanted after muscle pretreatment with metalloproteinases. Cell Transplant 9, 539-549.
121. Tremblay JP, Bouchard JP, Malouin F, Theau D, Cottrell F, Collin H, Rouche A, Gilgenkrantz S, Abbadi N, Tremblay M, Tomé FMS & Fardeau M (1993a). Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord 3, 583-592.
122. Tremblay JP, Malouin F, Roy R, Huard J, Bouchard JP, Satoh A & Richards CL (1993b). Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2, 99-112.
123. Vilquin JT, Asselin I, Guerette B, Kinoshita I, Lille S, Roy R & Tremblay JP (1994). Myoblast allotransplantation in mice: degree of success varies depending on the efficacy of various immunosuppressive treatments. Transplant Proc 26, 3372-3373.
124. Voisin V & de la Porte S (2005). [Pharmacological treatments for Duchenne and Becker dystrophies]. [Article in French.] J Soc Biol 199, 17-28.
125. Watt DJ, Lambert K, Morgan JE, Partridge TA & Sloper JC (1982). Incorporation of donor muscle precursor cells into an area of muscle regeneration in the host mouse. J Neurol Sci 57, 319-331.
126. Weir AP, Burton EA, Harrod G & Davies KE (2002). A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J Biol Chem 277, 45285-45290.
127. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang SW, Wilde RG, Karp G, Takasugi J, Chen GM, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW & Sweeney HL (2007). PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91.
128. Willmann R, Possekel S, Dubach-Powell J, Meier T & Ruegg MA (2009). Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19, 241-249.
129. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF, Sali A, Guerron AD, Nagaraju K, Doran T, Lu P, Xiao X & Lu QL (2008). Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A 105, 14814-14819.
130. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ & Lu QL (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17, 132-140.
131. Yang B, Jung D, Rafael JA, Chamberlain JS & Campbell KP (1995). Identification of α-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. J Biol Chem 270, 4975-4978.
132. Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N & Ikeda S (1999). Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 42, 145-149.
133. Yin H, Lu Q & Wood M (2008a). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther 16, 38-45.
134. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P & Wood MJ (2008b). Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 17, 3909-3918.
135. Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL & Wood MJ (2009). A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 18, 4405-4414.
136. Zhou L & Lu H (2010). Targeting fibrosis in Duchenne muscular dystrophy. J Neuropathol Exp Neurol 69, 771-776.